Anti-FGF21R Antibody (Efruxifermin)
Catalog No.
F2105
Anti-FGF21R Antibody (Efruxifermin)
Featured Products
Efruxifermin is a recombinant human fibroblast growth factor 21 (FGF21) analogue, mainly used to treat non-alcoholic steatohepatitis (NASH). Its mechanism is to activate the FGF21 signaling pathway, regulate metabolic processes, reduce liver fat accumulation and inflammatory response. Efruxifermin was developed by Akero Therapeutics, a US biotechnology company.
Quality Control & DataSheet
- View current batch:
Dry ice
2375240-92-7
-80°C
2 years
Liquid
1 mg/mL
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
AKR-001
100 mM Pro 20 mM Arg pH 5.0.
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
FGF21R
Please avoid freeze-thaw cycles.